TY - JOUR
T1 - Liquid biopsies for hepatocellular carcinoma
AU - Su, Ying Hsiu
AU - Kim, Amy K.
AU - Jain, Surbhi
N1 - Funding Information:
This work is supported by R01CA202769 ( YHS ), R43CA213610 ( SJ ), and R44CA165312 ( SJ ). We would like to thank Amy Lu and Gianni Aranoff for their assistance in manuscript preparation. All authors have read the journal's policy on disclosure of potential conflicts of interest. Ying-Hsiu Su and Amy K. Kim have no conflicts to disclose. Surbhi Jain is an employee of JBS Science, Inc. All authors have read the journal's authorship statement, and the manuscript has been reviewed by and approved by all named authors.
Funding Information:
This work is supported by R01CA202769 (YHS), R43CA213610 (SJ), and R44CA165312 (SJ). We would like to thank Amy Lu and Gianni Aranoff for their assistance in manuscript preparation. All authors have read the journal's policy on disclosure of potential conflicts of interest. Ying-Hsiu Su and Amy K. Kim have no conflicts to disclose. Surbhi Jain is an employee of JBS Science, Inc. All authors have read the journal's authorship statement, and the manuscript has been reviewed by and approved by all named authors.
Publisher Copyright:
© 2018
PY - 2018/11
Y1 - 2018/11
N2 - Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.
AB - Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver–cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.
UR - http://www.scopus.com/inward/record.url?scp=85050848942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050848942&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2018.07.001
DO - 10.1016/j.trsl.2018.07.001
M3 - Review article
C2 - 30056068
AN - SCOPUS:85050848942
SN - 1931-5244
VL - 201
SP - 84
EP - 97
JO - Translational Research
JF - Translational Research
ER -